HtmlToText
home company about us our investors our advisory board our management team oncotrip™ translational research oncomedics resources services oncogramme® personalized medicine r&d projects partnerships news & events vacancies contact us navigation menu bienvenue sur le site d'oncomedics une société de service dédiée à l'individualisation des traitements contre le cancer & à la recherche innovante en oncologie par le développement de modèles ex vivo . welcome to oncomedics a service company dedicated to the individualization of cancer treatment & to the support of scientific breakthroughs in oncology using ex vivo models. modèles dédiés à la recherche de candidats-médicaments ou de biomarqueurs cancer research models for drug candidates or biomarkers latest news our missions our management team 28-03-2017 the oncogramme® is now available for patients with metastatic colorectal cancer. this test is currently at the patient’s expense but oncomedics is actively working to obtain its reimbursement. read more 06-04-2016 oncomedics is in the news (in french) watch broadcast here: https://www.youtube.com/watch?v=afbhixad-3i read more 05-04-2016 the oncogramme® in 3 minutes (video in french) to better understand the oncogramme®, watch this video (in french): https://www.youtube.com/watch?v=yv4pz77q9y8 read more our mission is to extract the maximum of information from a fresh human tumor leading to the best possible treatment for the immediate benefit of the patient. despite great advances in our understanding of the cellular and molecular bases of human cancers and the increasing number of new therapeutic options, the treatment of advanced human cancers frequently remains disappointing, particularly when facing metastases. this is linked to the natural history of the tumors and/or patients, considering (i) the interpatient variability in drug exposure, (ii) the diversity of cancer subtypes with respect to molecular profiles, and (iii) the intratumoral heterogeneity, and (iv) the highly variable tumor cell doubling time. all these sources of variability make difficult the validation of markers predictive of the clinical response to the different therapeutic options including surgery, chemotherapy, targeted therapy, immunotherapy or radiotherapy. the interest of patient tumor established primary cell culture in preclinical and clinical testing is growing with the increasing number of new therapeutic alternatives. these primary cell cultures directly derived from patient tumor samples, with limited in vitro manipulation, provide a more accurate depiction of human tumor biologic characteristics than cell lines with high numbers of in vitro doubling periods. the unique experience of oncomedics allows the investigation of the sensitivity profile of the primary tumor cells anticipating the correlation with the clinical situation for each individual patient. oncomedics has secured all the legal and regulatory processes to collect and cultivate the fresh human tumors in a full legal frame. to facilitate these processes for his customers, oncomedics has developed a proprietary platform oncotrip, which has integrated all the required successive steps. with all these efforts, oncomedics provides a full and flexible analysis of the primary cultures of human tumors. in addition to this platform oncotrip, using its unique know-how, oncomedics has built a bank of living primary tumor cells and has optimized specific culture media to increase viability and growth of primary cells (oncomid-via, oncomid-diss, oncomid). in addition to these services, oncomedics develops its own pipeline of new primary cell culture products and services to extend the levels of investigation of the fresh human tumor cells. oncomedics is advancing its portfolio of research and development projects (biocaptor, imodi, oncogramme) on its own or through collaborative efforts with prestigious partners from the industrial world (sanofi, servier, pierre fabre, ipsen, transgene, onco design , cti-biotech, arianapharma, biofortis…) or from the academic institutions (universities, cnrs, inserm…). the figure below summarizes all the scientific and strategic interests of oncomedics to use the primary tumor cell cultures in a “clinical like trial” generating data potentially representative of the clinical trial results. chief executive officer: dr christophe lautrette christophe is doctor of the university of limoges (france) with a particular interest in biology-health. he is laureate of the thesis prize in 2003. in addition to his research activities, christophe has also held teaching positions at the university of limoges. christophe began to develop the technology supporting the oncogramme project at the university of limoges in the ea 3842, faculty of medicine of limoges. to complete his education, christophe participated to several entrepreneurial training organized by the doctoral school “health science technology” and the chamber of commerce and industry of limoges. then he integrated the limousin business incubator for the non-technical aspects. he especially participated to “challenge” of hec – paris (l’école des hautes études commerciales de paris, class 21) for training in all aspects of the creation of innovative companies (business, management, strategy, intellectual property, entrepreneurs network). he has continued his research work with more 10 scientific publications and patents dedicated to cellular homeostatis. christophe is holding the position of president oncomedics sas since its inception in august 2006. chief scientific officer: dr stéphanie giraud stéphanie is doctor of the university of limoges in biology and health. she also has experience of teaching at the university level (ater) and also of clinical research (arc) at the university hospital of limoges. stéphanie has actively participated to the creation of oncomedics with christophe. she is involved since 2004 mainly on its technical aspects. her research is oriented oncology and the study of the mechanisms of cell death and proliferation. stéphanie now controls all the technical research and development of oncomedics as chief scientific officer of oncomedics since its inception in august 2006. production director: dr christophe morand du puch christophe holds a bachelor of science from the college of charleston (south carolina, usa) and is also doctor of the university joseph fourier-grenoble i in chemistry-biology. christophe worked at previous positions on several programs of both academic research (college of charleston, charleston, inserm, paris, atomic energy commission, grenoble) and industrial research (atheris laboratories, geneva). his activities have enabled him to acquire a broad spectrum of expertise in cell biology, molecular biology, and biochemistry. his thesis focused on the study of the mechanisms of formation of chemical dna damage and repair of these lesions by cells in close contact with the therapeutic approaches of certain cancers. christophe joined oncomedics as project manager in january 2011, in charge of the hospital clinical research protocol on the method of oncogramme for colon cancer. comment se procurer l’oncogramme® ? en savoir plus home sitemap © oncomedics 2014
Informations Whois
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
Domain Name: ONCOMEDICS.COM
Registry Domain ID: 129877638_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.gandi.net
Registrar URL: http://www.gandi.net
Updated Date: 2016-07-15T12:20:36Z
Creation Date: 2004-09-13T14:36:05Z
Registry Expiry Date: 2018-09-13T14:36:05Z
Registrar: Gandi SAS
Registrar IANA ID: 81
Registrar Abuse Contact Email: abuse@support.gandi.net
Registrar Abuse Contact Phone: +33.170377661
Domain Status: ok https://icann.org/epp#ok
Name Server: NS1.DEVOPSYS.COM
Name Server: NS2.DEVOPSYS.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-09-03T03:42:12Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR Gandi SAS
SERVERS
SERVER com.whois-servers.net
ARGS domain =oncomedics.com
PORT 43
TYPE domain
RegrInfo
DOMAIN
NAME oncomedics.com
CHANGED 2016-07-15
CREATED 2004-09-13
STATUS
ok https://icann.org/epp#ok
NSERVER
NS1.DEVOPSYS.COM 85.14.152.4
NS2.DEVOPSYS.COM 85.14.152.5
REGISTERED yes
Go to top
oncomedics.com rapport :
Visitez le site